Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Xgeva® in healthy adults.

Detailed Description
-----------------
This is a phase I,single center, randomized, double-blind and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of QL1206 or Xgeva® in healthy volunteers. The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of QL1206 or Xgeva® in healthy volunteers. Meanwhile，observing the pharmacodynamic similarities of QL1206 or Xgeva® preliminarily. Subjects would receive a single 120mg（1.7ml） of QL1206 or through subcutaneous injection.

Official Title
-----------------
A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Conditions
-----------------
Healthy People

Intervention / Treatment
-----------------
* Drug: QL1206
* Drug: Xgeva®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sign the informed consent form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements; Aged ≥18 years or ≤50 years, male or female (including the boundary value); Agree to take effective contraceptive measures throughout the study period (including not limited to: hormonal drugs of pregnancy, physical contraception, surgery, abstinence, etc., until at least 6 months after the last study is administered; Clinical laboratory examination, chest X-ray, abdominal B-ultrasound, electrocardiogram, physical examination, vital signs and various examinations are normal or abnormal without clinical significance. Exclusion Criteria: Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously. Serum calcium levels are outside the normal range of the laboratory, or the subject uses calcium supplements in the screening period. The dental or jaw disease that is active, requiring oral surgery; or planned for invasive dental surgery during the study; or dental or oral surgery wounds have not healed; Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies, and Treponema pallidum antibodies;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: QL1206<br>QL1206 injection (120mg) by subcutaneous injection once on the first day. | Drug: QL1206<br>* subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.<br>|
| Active Comparator: Xgeva®<br>Xgeva® injection (120mg) by subcutaneous injection once on the first day. | Drug: Xgeva®<br>* subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.<br>* Other names: Denosumab Injection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the plasma concentration-time curve (AUC0-t ) | Area under the plasma concentration-time curve (AUC0-t ) from 0 o'clock to the last measurable concentration acquisition time t. | 134 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events(AE) | The adverse medical events that occur after the clinical trial subjects receive the test drug do not necessarily have a causal relationship with the treatment. | 134 day | 
| serum CTX1 | CTX1 is a serum type I collagen C-terminal peptide to detect the bone metastasis events. | 134 day |